Which medications are recommended to prevent asthma exacerbations?

Medications to Prevent Asthma Exacerbations

All patients with asthma should receive inhaled corticosteroid (ICS)-containing therapy as the foundation for preventing exacerbations, and short-acting beta-agonists (SABAs) should never be used alone. 12

Primary Prevention Strategy: ICS-Based Controller Therapy

The cornerstone of exacerbation prevention is regular ICS therapy, which has been proven highly effective at reducing exacerbation risk across all asthma severities 3. The evidence strongly supports that:

• ICS taken regularly reduces exacerbation risk more effectively than any other single intervention 3
• ICS + long-acting beta-agonist (LABA) combinations further reduce exacerbation risk beyond ICS alone 3
• Patients should NEVER use SABA as their only treatment, as this increases exacerbation risk despite providing symptom relief 4

Preferred Approach: Single Maintenance and Reliever Therapy (SMART/MART)

The most effective strategy for preventing exacerbations is using budesonide-formoterol (ICS-formoterol) as both maintenance therapy AND as-needed reliever therapy (called SMART or MART regimen) 35. This approach:

• Provides superior exacerbation reduction compared to traditional maintenance ICS + SABA reliever 3
• Works by delivering anti-inflammatory treatment precisely when symptoms worsen, during the critical "window of opportunity" before full exacerbation develops 6
• Is now the preferred Track 1 approach in GINA 2024 guidelines 72

Alternative Reliever Strategy: As-Needed ICS-SABA

For patients not on SMART therapy, the FDA recently approved albuterol-budesonide combination as an as-needed reliever (with or without separate maintenance therapy) 6. This represents a paradigm shift, allowing:

• Anti-inflammatory treatment with every reliever use
• Reduced exacerbation risk compared to SABA alone 6
• Decreased oral corticosteroid burden in moderate-to-severe asthma 6

Critical caveat: This combination is approved as reliever therapy only, NOT for maintenance therapy or SMART regimen 6.

Additional Exacerbation-Reducing Medications

Leukotriene Receptor Antagonists (LTRAs)

• Demonstrated to reduce severe exacerbations, particularly effective in children 3
• Can be added as adjunct controller therapy 5

Anti-IgE Monoclonal Antibodies (Omalizumab)

• Effective for reducing exacerbations in difficult-to-treat allergic asthma 3
• Reserved for severe uncontrolled allergic asthma despite optimal inhaled therapy 5

Anti-IL-5 Biologics

• Reduce severe exacerbations in eosinophilic asthma 3
• Target the approximately 50% of severe exacerbations that are eosinophilic in nature 3

Long-Acting Muscarinic Antagonists (LAMAs)

• Can be added as additional controller medication in stepwise therapy 5

Treatment Algorithm

1. Start all patients on ICS-containing therapy - never SABA alone 24
2. For mild asthma: Consider as-needed ICS-formoterol OR as-needed albuterol-budesonide 62
3. For moderate-severe asthma: Use SMART/MART with ICS-formoterol as both maintenance and reliever 25
4. If inadequately controlled: Add LTRA, LAMA, or increase ICS dose in stepwise fashion 5
5. For severe allergic/eosinophilic asthma: Consider biologics (anti-IgE or anti-IL-5) 35

Common Pitfalls to Avoid

• Never prescribe SABA as monotherapy - this is the most common error and significantly increases exacerbation risk 4
• Don't rely on patient adherence to separate maintenance ICS - patients frequently revert to SABA-only use, which is why reliever-containing ICS strategies are superior 4
• Don't use albuterol-budesonide for maintenance therapy - it's approved only as reliever 6
• Don't delay biologic referral in severe asthma - many patients with difficult-to-treat asthma are not referred early enough 2